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yl sulfoxide showed significant reduction in cell viability. 
 Conclusions: At clinical doses, neither ziv-aflibercept nor 
aflibercept caused any significant reduction in cell viability 
in vitro. Furthermore, injection solutions of NaCl with higher 
osmolality caused no significant reduction in cell viability. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 Ocular abnormal angiogenesis is the root of most of 
the main causes of blindness worldwide such as neovas-
cular age-related disease (AMD) and macular edema sec-
ondary to diabetes or vein occlusions  [1] . Vascular endo-
thelial growth factors (VEGF) are identified as the prin-
cipal mediators of new blood vessel growth and are key 
regulators of vascular permeability  [2] . The fusion pro-
teins, such as ziv-aflibercept (Zaltrap; Regeneron, Tarry-
town, NY, USA) and aflibercept (Eylea, Regeneron Phar-
 Keywords 
 Ziv-aflibercept · Aflibercept · Toxicity 
 Abstract 
 Purpose: The aim of this study was to access the safety pro-
files of 2 fusion proteins with anti-vascular endothelial 
growth factor action (ziv-aflibercept and aflibercept) on ret-
inal pigment epithelium cells and Muller-Glia cells in culture 
by assessing cell viability post drug exposure.  Methods: Pri-
mary human retinal pigment epithelium cells (pRPE) and 
Muller-Glia cells (Mio-M1) were exposed to the clinical stan-
dardized concentrations of ziv-aflibercept (25 mg/mL) and 
aflibercept (40 mg/mL). Progressively higher concentrations 
of NaCl (300, 500, 1,000, 1,500, 2,000, 5,000, and 10,000 
mosm/kg) were also applied to cells to assess the possibility 
of potentiating hyperosmotic cytotoxity effect. The study 
was applied to measure pRPE and Mio-M1 viability by a tet-
razolium dye-reduction assay (XTT).  Results: Cell viability of 
both pRPE and Mio-M1 presented no significant changes af-
ter exposure of ziv-aflibercept and aflibercept. Progressive 
NaCl concentrations did not significantly alter cell viability. 
The exposure to the negative control of 75 μL/mL of dimeth-
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maceuticals), are the most recent anti-angiogenic treat-
ment with some advantages compared to prior options, 
ranibizumab (Lucentis, Genentech) and bevacizumab 
(Avastin, Genentech) because it binds multiple members 
of the VEGF family, with high affinity for the VEGF-A 
and placental growth factor (PlGF) isoforms  [3] . These 
isoforms play a key role in the development of the choroi-
dal neovascularization associated with exudative AMD 
and in vascular hyperpermeability associated with macu-
lar edema  [4] . Additionally, the prolonged intravitreal 
half-life of aflibercept compared with ranibizumab can 
translate to a lower treatment load in terms of injections, 
monitoring, and medical visits  [4] .
 Ziv-aflibercept was approved by the FDA in August 
2012 for the treatment of patients with malignant colorec-
tal tumors  [5] . Its ophthalmic use is considered off-label. 
Ziv-aflibercept and aflibercept have the same structure 
and exert the same function, but aflibercept undergoes a 
different purification process and contains different buf-
fer solutions resulting in a compound of lower osmolality 
(300 vs. 1,000 mosm/kg) and possibly less toxicity  [6] . In 
order to assess the safety of ziv-aflibercept and other anti-
VEGF agents, Malik et al.  [7] conducted a study to evalu-
ate the effects of different concentrations of the four anti-
VEGF agents previously cited in an experimental model 
of human retinal pigment epithelium cells. The study 
showed mild toxicity of bevacizumab and ziv-aflibercept 
at clinical doses  [7] .
 Even after this in vitro study, consecutive clinical stud-
ies had been published demonstrating the safety and effi-
cacy of ziv-aflibercept in the treatment of macular diseas-
es  [8–10] . For instance, de Andrade et al.  [10]  showed 
good results in the treatment of diabetic macular edema 
with ziv-aflibercept resulting in improvement in best cor-
rected visual acuity (BCVA) and reduction in central reti-
nal thickness (CRT) and no signs of ocular or systemic 
toxicity in all treated patients. De Oliveira Dias et al.  [8] 
also tested ziv-aflibercept in a patient with AMD, also with 
improvement in BCVA and CRT and no signs of toxicity.
 The primary purpose of this study was to investigate 
the safety profiles of aflibercept and ziv-aflibercept on 
primary human retinal pigment epithelium cells (pRPE) 
and Muller-Glia cells (Mio-M1). The secondary goal of 
the study was to evaluate the potential toxicity of progres-
sively higher concentrations of NaCl (with different os-
molality) on pRPE and Mio-M1 cells. The method ap-
plied for the experiment was the tetrazolium dye-reduc-
tion (XTT) assay.
 Methods 
 Solutions of Different Osmolality: Aflibercept, Ziv-Aflibercept 
and Sterile NaCl 
 Aflibercept (Eylea ® , Bayer, Leverkusen, Germany) and ziv-
aflibercept (Zaltrap ® , Regeneron, Tarrytown, NY, USA) were used 















































































































 Fig. 1. The change in cell viability in the 
XTT assay observed for aflibercept or ziv-
aflibercept ( p > 0.05) in Muller-Glia cells in 
comparison to the control was not signifi-
cant. Furthermore, a change in osmolality 
in the injection solution up to 10,000 
mosm/kg did not cause any change in cell 
viability in comparison to the untreated 
control. A significant decrease was ob-





















   
   
   
   
   
   
   
   
   
   
   


























real injection, i.e., 40 and 25 mg/mL, respectively. The volume of 
the eye was set to be 6 mL. The clinical dose of aflibercept injected 
into the eye is 2 mg. Using this data, it was calculated that 8.33 μL 
of aflibercept and 13.3 μL of ziv-aflibercept must be applied to
1 mL of cell culture medium.  Sterile NaCl (B. Braun, Melsungen, 
Germany) was brought into solution using distilled water to pro-
duce different concentrations of salt solution: 300, 500, 1,000, 
1,500, 2,000, 5,000, and 10,000 mosm/kg. A dose of 75 μL/mL of 
dimethyl sulfoxide (DMSO) was used as a negative control.
 Cell Culture 
 pRPE cells and Mio-M1 cells were used and cultured in un-
coated cell culture flasks (NUNC, Langenselbold, Germany) in 
medium (Dulbecco’s Minimum Essential Medium, Biochrom AG, 
Berlin, Germany) containing 10% FCS and antibiotics (Biochrom 
AG, Berlin, Germany) under standard cell culture conditions. For 
the pRPE cells, only cells from the first three passages were used. 
Twenty-four hours after subdivision, the serum was removed fol-
lowed by another 24 h of incubation with the above described 
amount of agents under serum-free conditions.
 Isolation of Human Primary Retinal Pigment Epithelium Cells 
 Cadaver eyes from two human donors were obtained from the 
Munich University Hospital Eye Bank and processed within 4 to 
16 h of death. None of the donors had a known history of eye dis-
ease. Methods for securing human tissue were humane, included 
proper consent and approval, complied with the Declaration of 
Helsinki, and were approved by the local ethics committee. pRPE 
cells were extracted as described before  [11, 12] .
 Cell Viability Assay 
 In order to exclude any toxic effects of aflibercept, ziv-afliber-
cept, or higher osmolalities, it was carefully tested for its biocom-
patibility on pRPE and Mio-M1 cells in the XTT assay as described 
by Scudiero et al.  [13] and modified for ocular cell culture biocom-
patibility testing as described before  [12] .
 Statistical Analysis 
 Statistical comparison between different concentrations of 
Crocin, Resveratrol, and the control was done using the nonpara-
metric Mann-Whitney  U Test for comparison of two distinct 
groups. To prevent multiple testing in more than two subgroups, 
ANOVA with a Bonferroni post hoc test was used. For all analyses, 
 p < 0.05 was considered statistically significant with a 95% confi-
dence interval (CI). All graphs, if not stated otherwise, were plotted 
in Microsoft Excel showing the standard deviation as error bars. 
All statistical analysis was performed by SPSS 23.0.
 Results 
 Cell Viability 
 Cell viability was assessed to exclude any toxic effects 
of both formulations. No statistically significant decrease 
of cell viability was observed for Eylea or Zaltrap ( p > 
0.05) in all cell lines and in comparison to the control 
( Fig. 1–3 ). Furthermore, a change of osmolality in the in-
jection solution up to 10,000 mosm/kg did not cause any 
change in cell viability in comparison to the untreated 
control. The negative control of 75 μL/mL DMSO caused 
a consistent reduction in cell viability in comparison to 















































































































 Fig. 2. The change in cell viability in the 
XTT assay observed for aflibercept or ziv-
aflibercept ( p > 0.05) in primary human 
retinal pigment epithelium cells of donor 1 
in comparison to the control was not sig-
nificant. Furthermore, a change in osmo-
lality in the injection solution up to 10,000 
mosm/kg did not cause any change in cell 
viability in comparison to the untreated 
control. A significant decrease was ob-





















   
   
   
   
   
   
   
   
   
   
   


























trol;  p < 0.001; mean difference: 79.5%; 95% CI: 58–100%) 
(pRPE 1; control – negative control;  p < 0.001; mean dif-
ference: 71.4%; 95% CI: 58–85%) (pRPE 2; control – neg-
ative control;  p < 0.001; mean difference: 56.4%; 95% CI: 
38–75%).
 Discussion 
 The use of anti-VEGF agents has resulted in a dramat-
ic increase in intravitreal injections in recent years  [14] . 
An analysis of the Medicare claims database revealed few-
er than 5,000 intravitreal injections in 2001 and 812,413 
in 2007  [14] . Today, intravitreal injection is one of the 
most commonly performed medical procedures in the 
United States. More than 2.3 million intravitreal injec-
tions were performed in the United States in 2012, and 
projections call for more than 6 million annually by 2016 
 [15] . After the introduction of aflibercept, its use has been 
growing worldwide and besides the great clinical results, 
the costs regarding this therapy remain an important is-
sue.
 Ziv-aflibercept is a similar fusion protein and has 
shown promising results in the short term  [8, 9, 11] . In 
our previous study of intravitreal ziv-aflibercept for dia-
betic macular edema, all patients experienced improve-
ment in BCVA and decrease in CRT from baseline till 24 
weeks of follow-up  [11] . In a prospective noncomparative 
case series of 6 patients (4 with AMD and 2 with refrac-
tory diabetic macular edema), intravitreal ziv-aflibercept 
improved the visual acuity and decreased the central 
macular thickness. However, the follow-up was only 4 
weeks  [9] .
 The study by Malik et al.  [7] revealed mild toxicity of 
bevacizumab and ziv-aflibercept for human retinal pig-
ment epithelium cells (ARPE-19) and may have had a 
negative impact on the intravitreal use of ziv-aflibercept 
for macular diseases. In order to access the effect of ziv-
aflibercept in pRPE cells and also in Mio-M1 cells, we 
decided to compare its effect with aflibercept convention-
al intravitreal dose and progressive hyperosmolar solu-
tions of NaCl. Many reasons can explain the difference in 
results from our experiment in relation to Malik’s such as: 
different techniques of obtaining, isolation and culturing 
RPE cells, cell viability, contamination of the samples, 
technique, and time of exposure to anti-VEGF.
 In summary our study suggests that the exposure of 
ziv-aflibercept has no different effect on cell viability 
compared to aflibercept and hyperosmolar NaCl solu-
tions. Coupled with our recently published report of the 
lack of in vivo ocular toxicity in rabbits subjected to in-
travitreal ziv-aflibercept  [16] , as well as the lack of appar-
ent ocular toxicity seen in human eyes both from the ad-















































































































 Fig. 3. The change in cell viability in the 
XTT assay observed for aflibercept or ziv-
aflibercept ( p > 0.05) in primary human 
retinal pigment epithelium cells of donor 2 
in comparison to the control was not sig-
nificant. Furthermore, a change in osmo-
lality in the injection solution up to 10,000 
mosm/kg did not cause any change in cell 
viability in comparison to the untreated 
control. A significant decrease was ob-





















   
   
   
   
   
   
   
   
   
   
   


























off-label use  [8–-10] , all sources of testing suggest that 
ziv-aflibercept is not associated with significant ocular 
toxicity. However, formal testing of intravitreal ziv-
aflibercept in the context of randomized clinical trials is 
warranted before definitive statements regarding its safe-
ty and efficacy can be made.
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